Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Pharmacotherapy. 2022 Feb 24;42(3):272–279. doi: 10.1002/phar.2664

Fig 2: Treatment Outcomes for PTSD After Switch From Intranasal (S)-Ketamine to Intravenous (R,S)-Ketamine.

Fig 2:

A. We analyzed PCL-5 scores at four time-points of interest: immediately prior to the first dose of intranasal (S)-ketamine (pre-IN); immediately prior to the last-dose of intranasal (S)-ketamine (last-IN); immediately prior to the first dose of intravenous (R,S)-ketamine (pre-IV); immediately prior to the 6th dose of intravenous (R,S)-ketamine (6th-IV) There was a significant reduction in PCL-5scores driven by a change after switching to IV(R,S)-ketamine (p<0.05). B. Paired t-test was used to compare reductions in PCL-5 following (S)-ketamine, vs reductions following IV ketamine. IV (R,S) ketamine was significantly more effective (p<0.01). C. Repeated-measures ANOVA demonstrated a linear trend with treatment. D. Estimation plot demonstrates significant reductions in PCL-5 scores with continued treatment past the initial 6. Error bars represent SEM. *p<0.05; **p<−.01, ***p<0.001